For many patients, evidence-based approaches such as cognitive behavioral therapy for insomnia, circadian rhythm support, medication review, sleep apnea screening, mental health treatment, and lifestyle changes may be more appropriate than experimental peptide therapy
On the other hand, DPP-IV is responsible for the degradation of numerous signaling molecules such as endogenous opioid peptides including endorphins, dynorphins, and enkephalins which play crucial role in basic functions of the GI tract (e.g., motility, pain signaling, and secretion) (Saaga et al
[10] The bottom line is, if you dont know the ingredients, have no access to studies about potential side effects, and dont know where they are manufactured, it makes it very difficult to make an informed decision on whether or not to use a GLP-1 patch
AbbVie executed this strategy with Humira to near-perfection